Cancer Control Month 2025: Key Takeaways from President Trump’s National Call to Action

By Rene Pretorius

April 7, 2025

In this review, I unpack the content of President Donald J. Trump’s proclamation for Cancer Control Month 2025. The proclamation calls for a united national effort to prevent cancer, support patients, and accelerate cures. It honors those affected by cancer and emphasizes the urgency of reversing rising cancer rates through prevention, early detection, and breakthrough treatments. It also highlights the importance of personal responsibility, public awareness, and restoring trust in scientific research and innovation as foundational to reducing the burden of cancer in the United States.

Key Insights

The following key insights distill the main facts and messages from President Trump’s proclamation for Cancer Control Month 2025. Organized into three themes—epidemiology, health system response, and national priorities—they reflect the proclamation’s emphasis on current trends, institutional actions, and strategic direction in the fight against cancer.

Epidemiology: The Growing Cancer Burden

  • Cancer remains the second leading cause of death in the United States.

  • Adult cancer cases have risen by 88% since 1990, according to the Centers for Disease Control and Prevention.

  • Mortality rates for lung, colorectal, breast, and ovarian cancers are declining.
  • Risk factors include tobacco use, obesity, poor diet, physical inactivity, and exposure to carcinogens.

Health System Response: Progress and Public Health Action

  • The National Cancer Institute and Centers for Disease Control and Prevention continue to play vital roles in supporting cancer research and prevention.

  • The proclamation recognizes ongoing efforts to promote early detection, public awareness, and enabling treatment that leads to better outcomes.

Direction and Priorities for Cancer Control

  • The proclamation emphasizes the need to rebuild trust in science and medicine, particularly following the COVID-19 pandemic.

  • It underscores the importance of promoting healthy lifestyles, including good nutrition, regular physical activity, and tobacco cessation.

  • The President calls on all Americans—including government, industry, researchers, and individuals—to collaborate in preventing cancer and accelerating progress toward cures.

Conclusion

President Trump’s proclamation for Cancer Control Month 2025 reaffirms the nation’s commitment to reducing the burden of cancer. Emphasis is placed on prevention, early detection, and innovation. It highlights the importance of individual responsibility, public awareness, and scientific advancement in shaping future progress. Taken together, the proclamation reflects an understanding that cancer is not a challenge of isolated causes, but one shaped by interconnected factors—behavioral, environmental, institutional, and social. This month offers an opportunity for all sectors of society to engage in a shared, coordinated effort to honor those affected by cancer and accelerate meaningful change.

 

Reference url

Recent Posts

Long-Term HPV Vaccine Effectiveness: Sustained Protection Against Cervical Disease

By João L. Carapinha

March 19, 2026

HPV vaccine effectiveness is demonstrated in new clinical and real-world data from Merck, showcasing the sustained protection of GARDASIL®9 (9-valent Human Papillomavirus [HPV] vaccine) and GARDASIL® (4-valent HPV vaccine) against HPV-related cancers and diseases. Key findings include vaccine eff...
TAVI Reimbursement Expansion for Low- and Intermediate-Risk Patients: A New Era in Cardiovascular...
The TAVI reimbursement expansion announced by Zorginstituut Nederland on March 10, 2026, includes transcatheter aortic valve implantation (TAVI) in...
EU Approves Imfinzi Gastric Cancer Treatment as Perioperative Immunotherapy

By João L. Carapinha

March 17, 2026

Imfinzi gastric cancer treatment has received European Commission approval for adults with resectable, early-stage and locally advanced (Stages II, III, IVA) gastric and gastroesophageal junction (GEJ) cancers. AstraZeneca’s Imfinzi (durvalumab), a PD-L1 inhibitor, combined with FLOT chemotherapy...